Advanced search
Publication Cover
Leukemia & Lymphoma Volume 41, 2001 - Issue 3-4
Submit an article Journal homepage
99
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD

Antonio Rueda Service of Oncology, Hospital Clínico Universitario, MalagaCorrespondence[email protected]
,
Isabel Sevilla Service of Oncology, Hospital Clínico Universitario, Malaga
,
Josep Gumá Service of Oncology, Hospital Sant Joan, Reus, Tarragona
,
Nuria Ribelles Service of Oncology, Hospital Clínico Universitario, Malaga
,
JosÉ Miramón Department of Internal Medicine, Hospital de la Serranía, Ronda
,
Miguel A. De Las Nieves Unit of Hematology, Hospital Costa del Sol, Marbella, Malaga, Spain
,
Antonia Márquez Service of Oncology, Hospital Clínico Universitario, Malaga
&
Emilio Alba Service of Oncology, Hospital Clínico Universitario, Malaga
 show all
Pages 353-358 | Received 13 Aug 2000, Published online: 01 Jul 2009

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Mehul Dalal, Jatin Gupta, Kim Price, Athanasios Zomas, Harry Miao & Ajibade Ashaye. (2020) Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review. Expert Review of Hematology 13:8, pages 907-922.
Read now
Maja D. Andersen, Peter Kamper, Alexander d’Amore, Michael Clausen, Hans Bentzen & Francesco d'Amore. (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leukemia & Lymphoma 60:4, pages 927-933.
Read now
Leonard A. Minuk, Katherine Monkman, Ian H. Chin-Yee, Alejandro Lazo-Langner, Vinai Bhagirath, Benjamin H. Chin-Yee & Joy E. Mangel. (2012) Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leukemia & Lymphoma 53:1, pages 57-63.
Read now
Jyoti Nangalia, Hannah Smith & Jennie Z. Wimperis. (2008) Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leukemia & Lymphoma 49:8, pages 1530-1536.
Read now
Vikram K. Chand, Brian K. Link, Justine M. Ritchie, Mary Shannon & James E. Wooldridge. (2006) Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leukemia & Lymphoma 47:4, pages 657-663.
Read now

Articles from other publishers (10)

D. J. Straus. (2011) Chemotherapy only for localized Hodgkin lymphoma. Journal of Internal Medicine 270:3, pages 197-205.
Crossref
Andrew M. Evens & Sandra J. Horning. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 367 403 .
David J. Straus. (2009) The Case for Chemotherapy Only for Localized Hodgkin Lymphoma. The Oncologist 14:12, pages 1225-1231.
Crossref
Andrew M Evens, Martin Hutchings & Volker Diehl. (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nature Clinical Practice Oncology 5:9, pages 543-556.
Crossref
Amanda Wedgwood & Anas Younes. (2007) Prophylactic Use of Filgrastim with ABVD and BEACOPP Chemotherapy Regimens for Hodgkin Lymphoma. Clinical Lymphoma and Myeloma 8, pages S63-S66.
Crossref
Andrew M. Evens, Jeffrey Cilley, Taylor Ortiz, Mrinal Gounder, Nanjiang Hou, Alfred Rademaker, Sarah Miyata, Kara Catsaros, Connie Augustyniak, Charles L Bennett, Martin S. Tallman, Daina Variakojis, Jane N. Winter & Leo I. Gordon. (2007) G-CSF is not necessary to maintain over 99% dose?intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. British Journal of Haematology 137:6, pages 545-552.
Crossref
E. Boleti & G.M. Mead. (2007) ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Annals of Oncology 18:2, pages 376-380.
Crossref
Anas Younes, Luis Fayad, Jorge Romaguera, Barbara Pro, Andre Goy & Michael Wang. (2006) Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. European Journal of Cancer 42:17, pages 2976-2981.
Crossref
A. Rueda Domínguez, A. Márquez, J. Gumá, M. Llanos, J. Herrero, M.A. de las Nieves, J. Miramón & E. Alba. (2004) Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Annals of Oncology 15:12, pages 1798-1804.
Crossref
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:1, pages 43-50.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.